Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI

Executive Summary

CBER Office of Therapeutics Research & Review Acting Director Sharon Risso will continue to serve as the point person for biologics staff transition questions after the consolidation with FDA's drugs center
Advertisement

Related Content

FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
FDA names ODE VI deputy director
FDA names ODE VI deputy director
CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions
CBER Reviewers To Remain Accessible Post-Merger, CDER Tells BLA Sponsors
CDER Ad Division To Create Separate Biologics Review Group
CDER Office Of Biotech Products To Oversee Biologics Quality After Transition
CDER May Form New Office Of Drug Evaluation For CBER Reviewers
FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization
Advertisement
UsernamePublicRestriction

Register

PS041993

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel